EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparative evaluation of [68Ga]Ga-FAP-2286 and [18F]FDG PET/CT in breast cancer and initial experience with [177Lu]Lu-FAP-2286 therapy

Wei Liu, Na Zhang, Wenlu Zheng, Tingting Xu, Dong Huang, Zhiqiao Liu, Yue Chen iD

European Journal of Nuclear Medicine and Molecular Imaging · 2026-05 · 53 (6) · 3749-3759

DOI: 10.1007/s00259-026-07766-w ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 19.01.2026. Verfasst von Wei Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Fluorodeoxyglucose F18, Lutetium, Oligopeptides. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Innovative Research Group Project of the National Natural Science Foundation of China, Science and Technology Department of Gansu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Breast cancer is the most common malignancy among women and remains the leading cause of cancer-related death in this population. Radionuclide-based diagnostic and therapeutic approaches have emerged as effective and low-risk strategies for management of breast cancer. This study aimed to evaluate the diagnostic performance of [68Ga]Ga-FAP-2286 PET/CT compared with [18F]FDG PET/CT, and to provide a preliminary assessment of the clinical potential of [¹⁷⁷Lu]Lu-FAP-2286 radionuclide therapy in patients with advanced breast cancer. METHODS: A total of twenty patients with clinically suspected recurrent or metastatic breast cancer were prospectively enrolled. All participants underwent both [18F]FDG PET/CT and [68Ga]Ga-FAP-2286 PET/CT imaging within one week. The positivity rate of lesions, maximum standardized uptake value (SUVmax), and tumor-to-background ratio (TBR) were compared between the two imaging modalities across different involved organs. In addition, four patients received a single cycle of [¹⁷⁷Lu]Lu-FAP-2286 radionuclide therapy, and were followed for 4 months to assess therapeutic response and safety. RESULTS: The total number of lesions detected by [68Ga]Ga-FAP-2286 PET/CT was significantly higher than that detected by [18F]FDG PET/CT (85.4% vs. 70.5%, P 0.05). [177Lu]Lu-FAP-2286 demonstrated sustained high tumor uptake up to 168 h post-injection. In the four treated patients, the mean absorbed doses to tumor lesions were 0.21 ± 0.09, 0.27 ± 0.14, 0.14 ± 0.05, and 1.02 ± 0.30 Gy/GBq, respectively. Notably, in one patient, the total absorbed dose for all tumor lesions reached 54.23 Gy/GBq at 168 h. No grade III or IV adverse events were observed, and three of four patients exhibited stable disease (SD) on follow-up. CONCLUSION: [68Ga]Ga-FAP-2286 appears to be a promising imaging agent for breast cancer, while [177Lu]Lu-FAP-2286 may represent a potential therapeutic option for patients with advanced disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsFluorodeoxyglucose F18LutetiumOligopeptidesPositron Emission Tomography Computed TomographyAdultAgedFemaleHumansMiddle AgedGallium RadioisotopesRadioisotopesRadiopharmaceuticalsQuinolines

Stichwörter der Autor:innen

Breast cancerPET/CTPTRT[177Lu]Lu-FAP-2286[18F]FDG[68Ga]Ga-FAP-2286

Substanzen

68Ga-FAPIFluorodeoxyglucose F18Gallium RadioisotopesLutetiumLutetium-177OligopeptidesRadioisotopesRadiopharmaceuticalsQuinolines

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, China.
  • Department of Nuclear Medicine, The Second People's Hospital of Yibin, Yibin, 644000, Sichuan, China.
  • Nuclear Medicine and Theranostics Key Laboratory of Sichuan Province, Sichuan, 646000, Luzhou, China.
  • Institute of Nuclear Medicine, Southwest Medical University, No.25, Taiping St., Sichuan, 646000, Luzhou, PR China.
  • Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, China. liuzq93@swmu.edu.cn.
  • Nuclear Medicine and Theranostics Key Laboratory of Sichuan Province, Sichuan, 646000, Luzhou, China. liuzq93@swmu.edu.cn.

ORCID-Profile: Yue Chen

Förderung

  • Innovative Research Group Project of the National Natural Science Foundation of China
  • Science and Technology Department of Gansu Province

Zitieren

APA

Liu, W., Zhang, N., Zheng, W., Xu, T., Huang, D., Liu, Z., & Chen, Y. (2026). Comparative evaluation of [68Ga]Ga-FAP-2286 and [18F]FDG PET/CT in breast cancer and initial experience with [177Lu]Lu-FAP-2286 therapy. European Journal of Nuclear Medicine and Molecular Imaging, 53(6), 3749-3759. https://doi.org/10.1007/s00259-026-07766-w

Vancouver

Liu W, Zhang N, Zheng W, Xu T, Huang D, Liu Z, et al. Comparative evaluation of [68Ga]Ga-FAP-2286 and [18F]FDG PET/CT in breast cancer and initial experience with [177Lu]Lu-FAP-2286 therapy. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(6):3749-3759. doi:10.1007/s00259-026-07766-w

BibTeX
@article{Liu2026,
  author = {Liu, Wei and Zhang, Na and Zheng, Wenlu and Xu, Tingting and Huang, Dong and Liu, Zhiqiao and Chen, Yue},
  title = {Comparative evaluation of [68Ga]Ga-FAP-2286 and [18F]FDG PET/CT in breast cancer and initial experience with [177Lu]Lu-FAP-2286 therapy},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  volume = {53},
  number = {6},
  pages = {3749--3759},
  doi = {10.1007/s00259-026-07766-w}
}
Kostenlos starten →